PLCE1 and cancer: miR-328 suppresses the survival of cancer cells by targeting PLCE1 in esophageal cancer [16], inhibits epithelial to-mesenchymal transition in renal tubular cells by targeting CD44 [17, 27], and regulates cell invasion and proliferation in glioma cells by targeting SFRP1 [18] and in melanoma cells by targeting TGFb2 [19].